A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.
To evaluate the efficacy of ado-trastuzumab emtansine (T-DM1) among patients with advanced/metastatic HER2-amplified solid tumors. This was a single-center, non-randomized phase 2 basket trial conducted at Memorial Sloan Kettering Cancer Center.
To evaluate the efficacy of ado-trastuzumab emtansine (T-DM1) among patients with advanced/metastatic HER2-amplified solid tumors. This was a single-center, non-randomized phase 2 basket trial conducted at Memorial Sloan Kettering Cancer Center.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Genomics/Precision Medicine
- Maturity
- Potentially Practice-Changing
- Journal
- Clin Cancer Res
Why it surfaced
Matched watchlist topic 'Precision oncology and genomic medicine'. Study design: Randomized Controlled Trial (inferred). Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.